Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Blake

Showing results (801-810 of 895) with videos related to

Pageof 90
Sort By:
The American Journal of Surgical Pathology|July 16, 2014
The histomorphology of Lynch syndrome-associated ovarian carcinomas: toward a subtype-specific screening strategyMichael Herman Chui, Paul Ryan, Jordan Radigan, et al.
Breast Cancer Research and Treatment|October 4, 2007
Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 casesDmitry A Turbin, Samuel Leung, Maggie C U Cheang, et al.
Frontiers in Oncology|January 8, 2024
A tumor-restricted glycoform of podocalyxin is a highly selective marker of immunologically cold high-grade serous ovarian carcinomaJulyanne Brassard, Michael R Hughes, Pamela Dean, et al.
Oncogene|July 20, 2005
NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosisLeah M Prentice, Ashleen Shadeo, Valia S Lestou, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|December 7, 2016
Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine: Part 1: Fit-for-Purpose Approach to Classification of Clinical Immunohistochemistry BiomarkersCarol C Cheung, Corrado D'Arrigo, Manfred Dietel, et al.
BMC Cancer|January 23, 2008
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalitiesJoshua Z Press, Alessandro De Luca, Niki Boyd, et al.
The Journal of Pathology. Clinical Research|May 12, 2020
Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinomaAngela My Chan, Emeka Enwere, John B McIntyre, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|February 10, 2017
Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine - Part 2: Immunohistochemistry Test Performance CharacteristicsEmina E Torlakovic, Carol C Cheung, Corrado D'Arrigo, et al.
Breast Cancer Research and Treatment|February 6, 2016
Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptorBrandon S Sheffield, Zuzana Kos, Karama Asleh-Aburaya, et al.
Nature Communications|February 11, 2026
NKG2D upregulation sensitizes tumors to combined anti-PD1 and anti-VEGF therapy and prevents hearing lossSimeng Lu, Zhenzhen Yin, Limeng Wu, et al.
Pageof 90

Showing results (801-810 of 895) with videos related to

Sort By:
Pageof 90
The American Journal of Surgical Pathology|July 16, 2014
The histomorphology of Lynch syndrome-associated ovarian carcinomas: toward a subtype-specific screening strategyMichael Herman Chui, Paul Ryan, Jordan Radigan, et al.
Breast Cancer Research and Treatment|October 4, 2007
Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 casesDmitry A Turbin, Samuel Leung, Maggie C U Cheang, et al.
Frontiers in Oncology|January 8, 2024
A tumor-restricted glycoform of podocalyxin is a highly selective marker of immunologically cold high-grade serous ovarian carcinomaJulyanne Brassard, Michael R Hughes, Pamela Dean, et al.
Oncogene|July 20, 2005
NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosisLeah M Prentice, Ashleen Shadeo, Valia S Lestou, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|December 7, 2016
Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine: Part 1: Fit-for-Purpose Approach to Classification of Clinical Immunohistochemistry BiomarkersCarol C Cheung, Corrado D'Arrigo, Manfred Dietel, et al.
BMC Cancer|January 23, 2008
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalitiesJoshua Z Press, Alessandro De Luca, Niki Boyd, et al.
The Journal of Pathology. Clinical Research|May 12, 2020
Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinomaAngela My Chan, Emeka Enwere, John B McIntyre, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|February 10, 2017
Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine - Part 2: Immunohistochemistry Test Performance CharacteristicsEmina E Torlakovic, Carol C Cheung, Corrado D'Arrigo, et al.
Breast Cancer Research and Treatment|February 6, 2016
Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptorBrandon S Sheffield, Zuzana Kos, Karama Asleh-Aburaya, et al.
Nature Communications|February 11, 2026
NKG2D upregulation sensitizes tumors to combined anti-PD1 and anti-VEGF therapy and prevents hearing lossSimeng Lu, Zhenzhen Yin, Limeng Wu, et al.
Pageof 90